Paolo Tarantino shared a post by Florian Muller, Co-Head of Biology at Powder Gate Discovery, on X adding:

“Truly groundbreaking work that turned a failed chemotherapy in one of the most active anticancer drugs ever developed.”

Quoting Florian Muller’s post:

“To think that Exatecan failed miserably as a stand-alone cancer drug. Two people turned the lemon into lemonade: Ogitani and Agastsuma – to this day, completely unknown outside of Daiichi Sankyo.”

Additional information.
Source: Paolo Tarantino/X and Florian Muller/X

Dr. Paolo Tarantino, MD researcher, holds positions at both the European Institute of Oncology in Milan, Italy, and the Dana-Farber Cancer Institute in Boston, MA, Specializing in breast cancer. Currently, Dr. Tarantino is pursuing an advanced research fellowship at Dana-Farber Cancer Institute and Harvard Medical School, concurrently working towards a PhD in clinical research at the University of Milan. His research focuses on exploring the HER2 oncoprotein, investigating the emerging HER2-low subgroup of breast tumors, and developing novel antibody-drug conjugates targeting every subtype of breast cancer. With a robust publication record exceeding 50 papers on breast cancer, he is recognized as a leading expert in the field. Dr. Tarantino’s dedication and innovative approach contribute significantly to the advancement of breast cancer treatment and research.